Leslie BHA2026-02-17T14:01:03-05:00— Proceeds to support advancement of lead cell therapy program for Geographic Atrophy and next-generation hydrogel regenerative therapy platform —
— Partnership with global pharmaceutical company will leverage GelMEDIX regenerative medicine technology to develop stem cell-derived cell therapies —
CAMBRIDGE, Mass., Feb. 17, 2026 /PRNewswire/ -- GelMEDIX, Inc., a biotechnology company developing regenerative therapies to restore vision, announced today the completion of a $13 million seed financing led by Safar Partners, with participation from HTL Biotechnology, Beacon Angels, TiE Boston Angels, Boston Harbor...
